BioBridgeX
Log inCompare quotes
Modality

Peptide CRO and CDMO vendors

Free for buyersNeutral marketplace
Quick answer

Outsourcing a peptide program means matching a CRO or CDMO to solid-phase or solution-phase synthesis, purification, and the analytical work that proves identity and purity. It spans discovery synthesis through GMP drug substance, fill-finish, and stability. On BioBridgeX, buyers source and compare qualified peptide suppliers, free for buyers, and contract directly with the supplier they choose.

Peptide CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Peptide CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What does it take to develop and manufacture a peptide drug?

Peptides sit in an awkward middle ground between small molecules and biologics, and that is exactly why supplier fit matters so much. A peptide is built one amino acid at a time, usually by solid-phase peptide synthesis (SPPS), and every coupling step is a chance to introduce a deletion sequence, a racemized residue, or an aggregation problem you will spend weeks chasing later. The chemistry that makes a clean 12-mer is not the chemistry that makes a 40-residue therapeutic with three disulfide bridges, a lipid conjugate, or a head-to-tail cyclization. So the first thing to settle with any provider is whether they have actually made molecules like yours, at the length and complexity you need, not whether they run a peptide synthesizer.

Early on, the work is discovery and optimization: sequence design, analog synthesis, stability and protease-resistance screening, and the modifications that turn a fragile native peptide into a drug (N-methylation, unnatural amino acids, PEGylation or lipidation for half-life, cyclization for rigidity and target selectivity). This is largely non-GLP, decision-grade chemistry, and a discovery-focused peptide CRO lives here. As you move toward the clinic, the center of gravity shifts to CMC and manufacturing: a defined synthesis route, validated purification (almost always preparative reverse-phase HPLC), and an analytical package that nails down identity, purity, counterion and water content, and the impurity profile. Mass spec, analytical HPLC, amino acid analysis, and chiral or peptide-mapping methods all earn their place here.

This is where specialist peptide CDMOs pull away from generalist chemical manufacturers. A shop that is excellent at small-molecule API may underestimate how much a peptide program lives or dies on purification capacity and on controlling closely related impurities (single-residue deletions, oxidation, diastereomers) that a routine HPLC method will not even separate. Specialists bring large-scale SPPS or hybrid solution-phase routes, the prep-HPLC and lyophilization throughput to actually make kilograms, and analysts who have characterized these impurity classes before. Longer or more modified peptides push you firmly toward a specialist; a short, simple linear peptide gives you more room to use a capable generalist.

How do you choose a CRO or CDMO for peptide work?

Start with fit to your specific molecule, not the size of the logo or the headline price. Score two or three suppliers against the same written scope (the sequence, the length, the modifications, the scale, and the purity spec you need) so the quotes measure the same work rather than three differently shaped guesses. The cheapest quote on a complex peptide is rarely the cheapest outcome, because a failed batch or an impurity you cannot clear forces a repeat that costs you months. Work the checklist below.

  • Relevant platform and track record: confirm they routinely make peptides of your length and type (linear, cyclic, stapled, disulfide-rich, conjugated or lipidated) and ask to see comparable structures they have produced, not a generic capabilities slide. SPPS depth, plus solution-phase or hybrid routes for longer sequences and larger scale, is the real differentiator.
  • GxP status and analytical capability for this modality: match the quality system to your stage. Research analogs run non-GLP; IND-enabling and clinical material need GMP drug substance with full release testing. Confirm the analytical toolkit handles peptides specifically: prep and analytical RP-HPLC, LC-MS and high-res mass spec, amino acid analysis, peptide mapping, counterion and water (Karl Fischer) content, and methods that resolve deletion sequences and diastereomers, not just a single purity number.
  • Capacity and scale: ask how much they can actually make at your stage and whether they can carry you from grams to kilograms without a technology transfer to a different site. Purification throughput (prep-HPLC columns and loading) and lyophilization capacity are the usual bottlenecks, so probe those, not just synthesizer count. Check current queue and realistic lead time, since a strong lab booked solid can be slower than a good lab with an open slot.
  • Regulatory experience: for clinical material, confirm they have supported INDs or equivalent filings with peptide drug substance, can supply the CMC sections and method validation a regulator will scrutinize, and understand the impurity qualification and specification-setting that peptides demand. Stability program design and ICH-aligned storage data matter once you are in the clinic.
  • IP and confidentiality: get a CDA in place before you disclose your sequence, since the sequence itself is the asset. Settle ownership of process know-how, any supplier-developed synthesis or purification improvements, and the analytical methods, in writing before work starts.

Frequently asked questions

Do I need a specialist peptide CDMO, or can a generalist chemical manufacturer handle it?
It depends on the molecule. A short, simple linear peptide with a standard purity spec is well within reach of a capable generalist that runs SPPS. Once you add length (roughly past 20 to 30 residues), cyclization, multiple disulfide bonds, unnatural amino acids, or a lipid or PEG conjugate, the program leans hard on specialist capability: purification capacity to clear closely related impurities, analysts who have characterized peptide impurity classes before, and routes that scale to kilograms. The honest test is whether the supplier has made molecules like yours at the scale you need, not whether they own a peptide synthesizer.
What is the difference between solid-phase and solution-phase peptide synthesis, and why does it matter?
Solid-phase peptide synthesis (SPPS) builds the chain on a resin, one amino acid at a time, and is the default for most therapeutic peptides because it is fast and well controlled. Solution-phase synthesis couples fragments in solution and is often used for shorter sequences or, in hybrid form, to make longer peptides at larger scale more economically. It matters because the route affects cost, scalability, and impurity profile. Many large-scale commercial peptides use a hybrid approach. Ask a prospective supplier which route they would propose for your sequence and scale, and why.
What analytical testing should a peptide drug substance go through?
At minimum: identity by mass spec and amino acid analysis, purity and the impurity profile by analytical reverse-phase HPLC, plus characterization of the impurities that matter for peptides specifically (single-residue deletion sequences, oxidation, and diastereomers from racemization). You also need counterion content, water content by Karl Fischer, peptide content or assay, and for clinical material a stability program. Methods that report one purity number without resolving closely related impurities are a red flag, since those impurities are exactly where peptides get into trouble.
When does a peptide program need GMP manufacturing?
Discovery and optimization, where you make analogs to screen sequence, stability, and potency, runs non-GLP under good scientific practice. You need GMP drug substance once you are making material for IND-enabling toxicology and, certainly, for clinical trials, where the synthesis route, purification, release testing, and stability all have to meet regulatory standards. Map your scale-up milestones early, because moving from research-grade analog work to GMP material can mean a technology transfer if your discovery CRO does not also have GMP capacity.
How do I keep my peptide sequence confidential when I send it to a supplier?
Put a CDA in place before you disclose the sequence, because the sequence is the core IP and is sensitive the moment it leaves your hands. Beyond the CDA, settle in writing who owns any process know-how, synthesis or purification improvements the supplier develops on your program, and the analytical methods. Reputable peptide CROs and CDMOs handle confidential sequences routinely and will not balk at a CDA before scoping. On BioBridgeX you can review supplier profiles and capabilities before any sequence changes hands.
How does sourcing peptide suppliers on BioBridgeX work, and what does it cost buyers?
You describe the work (your sequence characteristics, length, modifications, scale, purity spec, and stage) and get matched with qualified peptide CROs and CDMOs that can actually do it. You compare them on relevant track record, GxP and analytical capability, capacity, and transparent quotes, with supplier profiles openly discoverable rather than locked behind a demo. BioBridgeX is the neutral marketplace and is free for buyers; suppliers pay a flat 2% platform fee, so quotes are not padded with buyer-side markups. If your program also needs DMPK, bioanalytical, or formulation work alongside synthesis, you can source it all and compare quotes and contract directly with each chosen supplier in one place.

Source Peptide work with one contract

Compare transparent quotes from qualified Peptide CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes